{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T04:27:27Z","timestamp":1792902447034,"version":"4.5.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.humimm.2024.111207","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T05:52:04Z","timestamp":1733982724000},"page":"111207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chimeric antigen receptor natural killer cell therapy: A systematic review of preclinical studies for hematologic and solid malignancies"],"prefix":"10.1016","volume":"86","author":[{"given":"Arezoo","family":"Karamivandishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Hatami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Masoud","family":"Eslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Izadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.humimm.2024.111207_bb0005","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.humimm.2024.111207_bb0010","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/ijp.ijp_531_20","article-title":"Chimeric antigen receptor T cell: A cancer immunotherapy","volume":"54","author":"Singh","year":"2022","journal-title":"Indian J. Pharm."},{"issue":"4","key":"10.1016\/j.humimm.2024.111207_bb0015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/cancers13040743","article-title":"Adoptive immunotherapy beyond CAR T-cells","volume":"13","author":"Titov","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.humimm.2024.111207_bb0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2024.111207_bb0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1188\/17.CJON.S2.29-34","article-title":"Cytokine release syndrome: inpatient care for side effects of CAR T-cell therapy","volume":"21","author":"Smith","year":"2017","journal-title":"Clin. J. Oncol. Nurs."},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.humimm.2024.111207_bb0040","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.humimm.2024.111207_bb0045","doi-asserted-by":"crossref","unstructured":"Romee, R., et al., Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci. Transl. Med. 2016. 8(357): p. 357ra123-357ra123.","DOI":"10.1126\/scitranslmed.aaf2341"},{"issue":"7229","key":"10.1016\/j.humimm.2024.111207_bb0050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature07665","article-title":"Adaptive immune features of natural killer cells","volume":"457","author":"Sun","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.humimm.2024.111207_bb0055","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s11684-018-0653-9","article-title":"Challenges of NK cell-based immunotherapy in the new era","volume":"12","author":"Fang","year":"2018","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0060","doi-asserted-by":"crossref","first-page":"12171","DOI":"10.1038\/ncomms12171","article-title":"Human NK cell development requires CD56-mediated motility and formation of the developmental synapse","volume":"7","author":"Mace","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.humimm.2024.111207_bb0065","doi-asserted-by":"crossref","unstructured":"Hu, Y., Z. Tian, and C.J.E. Zhang, Natural killer cell-based immunotherapy for cancer: advances and prospects. Semin. Immunol. 2019. 5(1): p. 106\u2013114.","DOI":"10.1016\/j.eng.2018.11.015"},{"key":"10.1016\/j.humimm.2024.111207_bb0070","doi-asserted-by":"crossref","first-page":"1231916","DOI":"10.3389\/fimmu.2023.1231916","article-title":"KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors","volume":"14","author":"Mac Donald","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.111207_bb0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/jitc-2023-007502","article-title":"Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies","volume":"11","author":"Hasan","year":"2023","journal-title":"J. Immunother Cancer"},{"issue":"8","key":"10.1016\/j.humimm.2024.111207_bb0080","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/07357907.2018.1515315","article-title":"Natural killer cell-based cancer immunotherapy: a review on 10 years completed clinical trials","volume":"36","author":"Suen","year":"2018","journal-title":"Cancer Investig."},{"issue":"21","key":"10.1016\/j.humimm.2024.111207_bb0085","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.humimm.2024.111207_bb0090","first-page":"545","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.111207_bb0095","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s12015-021-10246-3","article-title":"Chimeric antigen receptor-engineered natural killer (CAR NK) cells in cancer treatment; recent advances and future prospects","volume":"17","author":"Elahi","year":"2021","journal-title":"Stem Cell Rev. Rep."},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41419-024-06438-7","article-title":"Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.humimm.2024.111207_bb0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.humimm.2024.111207_bb0110","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/01.STR.0000125719.25853.20","article-title":"Pooling of animal experimental data reveals influence of study design and publication bias","volume":"35","author":"Macleod","year":"2004","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.humimm.2024.111207_bb0115","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/CJI.0000000000000286","article-title":"Anti-\u03b1FR CAR-engineered NK-92 cells display potent cytotoxicity against \u03b1FR-positive ovarian Cancer","volume":"42","author":"Ao","year":"2019","journal-title":"J. Immunother."},{"issue":"14","key":"10.1016\/j.humimm.2024.111207_bb0120","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.7150\/ijbs.64630","article-title":"Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer","volume":"17","author":"Cao","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0125","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbrc.2020.01.053","article-title":"Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer","volume":"524","author":"Cao","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.humimm.2024.111207_bb0130","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/08923970601066971","article-title":"Cytolytic and cytotoxic activity of a human natural killer cell line genetically modified to specifically recognize HER-2\/neu overexpressing tumor cells","volume":"28","author":"Demirtzoglou","year":"2006","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000450","article-title":"PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations","volume":"8","author":"Fabian","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"176","key":"10.1016\/j.humimm.2024.111207_bb0140","doi-asserted-by":"crossref","first-page":"405","DOI":"10.24976\/Discov.Med.202335176.41","article-title":"Development of FAP-targeted chimeric antigen receptor NK-92 cells for non-small cell lung Cancer","volume":"35","author":"Fang","year":"2023","journal-title":"Discov. Med."},{"issue":"45","key":"10.1016\/j.humimm.2024.111207_bb0145","article-title":"Nanobody-engineered natural killer cell conjugates for solid tumor adoptive immunotherapy","volume":"17","author":"Gong","year":"2021","journal-title":"Small"},{"issue":"7","key":"10.1016\/j.humimm.2024.111207_bb0150","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.medj.2023.04.004","article-title":"A chimeric antigen receptor uniquely recognizing MICA\/B stress proteins provides an effective approach to target solid tumors","volume":"4","author":"Goulding","year":"2023","journal-title":"Med"},{"issue":"10","key":"10.1016\/j.humimm.2024.111207_bb0155","article-title":"Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors. Journal for immunotherapy of","volume":"9","author":"Jan","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.humimm.2024.111207_bb0160","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.omtm.2023.03.006","article-title":"Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles","volume":"29","author":"Jo","year":"2023","journal-title":"Mol. Ther Methods Clin. Dev."},{"key":"10.1016\/j.humimm.2024.111207_bb0165","doi-asserted-by":"crossref","first-page":"1089369","DOI":"10.3389\/fimmu.2022.1089369","article-title":"A modifiable universal cotinine-chimeric antigen system of NK cells with multiple targets","volume":"13","author":"Kang","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2024.111207_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006130","article-title":"Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6","volume":"11","author":"Lee","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.humimm.2024.111207_bb0175","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00262-022-03275-5","article-title":"TCR extracellular domain genetically linked to CD28, 2B4\/41BB and DAP10\/CD3\u03b6 -engineered NK cells mediates antitumor effects","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.humimm.2024.111207_bb0180","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","article-title":"KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape","volume":"28","author":"Li","year":"2022","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0185","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3892\/or.2020.7862","article-title":"Specific growth inhibition of ErbB2-expressing human breast cancer cells by genetically modified NK-92 cells","volume":"33","author":"Liu","year":"2015","journal-title":"Oncol. Rep."},{"issue":"47","key":"10.1016\/j.humimm.2024.111207_bb0190","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add1187","article-title":"Successful targeting of PD-1\/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model","volume":"8","author":"Liu","year":"2022","journal-title":"Sci. Adv."},{"issue":"13","key":"10.1016\/j.humimm.2024.111207_bb0195","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An oncolytic virus expressing IL15\/IL15R\u03b1 combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.humimm.2024.111207_bb0200","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ebiom.2019.01.031","article-title":"NK cells specifically TCR-dressed to kill cancer cells","volume":"40","author":"Mensali","year":"2019","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0205","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41598-020-59082-4","article-title":"\u201cUniCAR\u201d-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells","volume":"10","author":"Mitwasi","year":"2020","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.humimm.2024.111207_bb0210","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/cells9061382","article-title":"Anti-PSMA CAR-engineered NK-92 cells: an off-the-shelf cell therapy for prostate cancer","volume":"9","author":"Montagner","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.humimm.2024.111207_bb0215","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/eji.201948140","article-title":"Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer","volume":"49","author":"Parlar","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.humimm.2024.111207_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106656","article-title":"Engineering c-met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma","volume":"188","author":"Peng","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.humimm.2024.111207_bb0225","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s00262-022-03183-8","article-title":"Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors","volume":"71","author":"Prasad","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.humimm.2024.111207_bb0230","first-page":"9","article-title":"Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells","author":"Robbins","year":"2020","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.humimm.2024.111207_bb0235","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00262-015-1669-5","article-title":"Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma","volume":"64","author":"Seidel","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0240","doi-asserted-by":"crossref","first-page":"2127508","DOI":"10.1080\/2162402X.2022.2127508","article-title":"AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma","volume":"11","author":"Strecker","year":"2022","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.humimm.2024.111207_bb0245","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1053\/j.gastro.2021.12.281","article-title":"Off-the-shelf prostate stem cell antigen-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic Cancer","volume":"162","author":"Teng","year":"2022","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.humimm.2024.111207_bb0250","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","article-title":"DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy","volume":"194","author":"T\u00f6pfer","year":"2015","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.humimm.2024.111207_bb0255","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/cas.14374","article-title":"Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer\/innate lymphoid cells","volume":"111","author":"Ueda","year":"2020","journal-title":"Cancer Sci."},{"issue":"45","key":"10.1016\/j.humimm.2024.111207_bb0260","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107507118","article-title":"Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells","volume":"118","author":"Wang","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.humimm.2024.111207_bb0265","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/cac2.12321","article-title":"The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death","volume":"42","author":"Wu","year":"2022","journal-title":"Cancer Commun. (Lond)"},{"issue":"11","key":"10.1016\/j.humimm.2024.111207_bb0270","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.21873\/anticanres.13796","article-title":"Robo1-specific CAR-NK immunotherapy enhances efficacy of (125)I seed brachytherapy in an Orthotopic mouse model of human pancreatic carcinoma","volume":"39","author":"Xia","year":"2019","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.humimm.2024.111207_bb0275","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ymthe.2017.12.012","article-title":"Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma","volume":"26","author":"Yu","year":"2018","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.humimm.2024.111207_bb0280","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv375","article-title":"ErbB2\/HER2-specific NK cells for targeted therapy of glioblastoma","volume":"108","author":"Zhang","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.humimm.2024.111207_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002980","article-title":"Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity","volume":"9","author":"Zhang","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.humimm.2024.111207_bb0290","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/icb.2013.45","article-title":"Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody","volume":"91","author":"Zhang","year":"2013","journal-title":"Immunol. Cell Biol."},{"issue":"6","key":"10.1016\/j.humimm.2024.111207_bb0295","first-page":"3714","article-title":"Bortezomib improves adoptive carbonic anhydrase IX-specific chimeric antigen receptor-modified NK92 cell therapy in mouse models of human renal cell carcinoma","volume":"40","author":"Zhang","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.humimm.2024.111207_bb0300","doi-asserted-by":"crossref","first-page":"4263520","DOI":"10.1155\/2018\/4263520","article-title":"Combination therapy with EpCAM-CAR-NK-92 cells and Regorafenib against human colorectal Cancer models","volume":"2018","author":"Zhang","year":"2018","journal-title":"J Immunol Res"},{"issue":"4","key":"10.1016\/j.humimm.2024.111207_bb0305","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-022-00660-2","article-title":"Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia","volume":"12","author":"Albinger","year":"2022","journal-title":"Blood Cancer J."},{"issue":"10","key":"10.1016\/j.humimm.2024.111207_bb0310","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26527","article-title":"Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity","volume":"2","author":"Boissel","year":"2013","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0315","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","article-title":"Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia","volume":"15","author":"Caruso","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"35","key":"10.1016\/j.humimm.2024.111207_bb0320","doi-asserted-by":"crossref","first-page":"56219","DOI":"10.18632\/oncotarget.11019","article-title":"Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.humimm.2024.111207_bb0325","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.humimm.2024.111207_bb0330","doi-asserted-by":"crossref","first-page":"37128","DOI":"10.18632\/oncotarget.16201","article-title":"Gene-modified NK-92MI cells expressing a chimeric CD16-BB-\u03b6 or CD64-BB-\u03b6 receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.humimm.2024.111207_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.humimm.2024.111207_bb0340","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.humimm.2024.111207_bb0345","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/2326-6066.CIR-14-0114","article-title":"Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice","volume":"3","author":"Chu","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"10.1016\/j.humimm.2024.111207_bb0350","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1341031","article-title":"Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice","volume":"6","author":"Chu","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0355","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1038\/s41467-022-35127-2","article-title":"Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma","volume":"13","author":"Cichocki","year":"2022","journal-title":"Nat. Commun."},{"issue":"23","key":"10.1016\/j.humimm.2024.111207_bb0360","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.2021015184","article-title":"Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","volume":"140","author":"Cichocki","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.humimm.2024.111207_bb0365","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.humimm.2024.111207_bb0370","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol. Oncol."},{"issue":"6","key":"10.1016\/j.humimm.2024.111207_bb0375","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3892\/ol.2023.13822","article-title":"CD19\/CD22 bispecific chimeric antigen receptor-NK-92 cells are developed and evaluated","volume":"25","author":"Kim","year":"2023","journal-title":"Oncol. Lett."},{"issue":"8","key":"10.1016\/j.humimm.2024.111207_bb0380","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","article-title":"NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.humimm.2024.111207_bb0385","article-title":"GMP-compliant universal antigen presenting cells (uAPC) promote the metabolic fitness and antitumor activity of armored cord blood CAR-NK cells","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2024.111207_bb0390","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.humimm.2024.111207_bb0395","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jcyt.2020.06.003","article-title":"Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.humimm.2024.111207_bb0400","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3390\/v13071365","article-title":"Improved activity against acute myeloid leukemia with chimeric antigen receptor (CAR)-NK-92 cells designed to target CD123","volume":"13","author":"Morgan","year":"2021","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.humimm.2024.111207_bb0405","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.21873\/anticanres.14304","article-title":"KHYG-1 cells with EGFRvIII-specific CAR induced a pseudoprogression-like feature in subcutaneous tumours derived from glioblastoma-like cells","volume":"40","author":"Nakazawa","year":"2020","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.humimm.2024.111207_bb0410","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jcyt.2016.10.009","article-title":"Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma","volume":"19","author":"Oelsner","year":"2017","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.humimm.2024.111207_bb0415","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/ijc.32269","article-title":"Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth","volume":"145","author":"Oelsner","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"68","key":"10.1016\/j.humimm.2024.111207_bb0420","doi-asserted-by":"crossref","first-page":"112783","DOI":"10.18632\/oncotarget.22626","article-title":"Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells","volume":"8","author":"Pinz","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.humimm.2024.111207_bb0425","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-019-0613-7","article-title":"Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia","volume":"34","author":"Quintarelli","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0430","article-title":"Therapeutic targeting of follicular T cells with chimeric antigen receptor-expressing natural killer cells","volume":"1","author":"Reighard","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.humimm.2024.111207_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.847008","article-title":"Genetic engineering and enrichment of human NK cells for CAR-enhanced immunotherapy of hematological malignancies","volume":"13","author":"Soldierer","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.humimm.2024.111207_bb0440","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000596","article-title":"CD38-specific chimeric antigen receptor expressing natural killer KHYG-1 cells: a proof of concept for an \u201coff the shelf\u201d therapy for multiple myeloma","volume":"5","author":"Stikvoort","year":"2021","journal-title":"HemaSphere"},{"issue":"3","key":"10.1016\/j.humimm.2024.111207_bb0445","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/cancers14030524","article-title":"Increased activity of a NK-specific CAR-NK framework targeting CD3 and CD5 for T-cell leukemias","volume":"14","author":"Voynova","year":"2022","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.humimm.2024.111207_bb0450","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/bloodadvances.2020001510","article-title":"Inducible MyD88\/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells","volume":"4","author":"Wang","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0455","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-019-0732-7","article-title":"2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies","volume":"12","author":"Xu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.humimm.2024.111207_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216103","article-title":"Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia","volume":"558","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"issue":"45","key":"10.1016\/j.humimm.2024.111207_bb0465","doi-asserted-by":"crossref","first-page":"17481","DOI":"10.1073\/pnas.0804788105","article-title":"Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas","volume":"105","author":"Kruschinski","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0470","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.humimm.2024.111207_bb0475","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"68","key":"10.1016\/j.humimm.2024.111207_bb0480","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.22626","article-title":"Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells","volume":"8","author":"Pinz","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.humimm.2024.111207_bb0485","series-title":"A modifiable universal cotinine-chimeric antigen system of NK cells with multiple targets","first-page":"1089369","volume":"13","author":"Kang","year":"2023"},{"issue":"3","key":"10.1016\/j.humimm.2024.111207_bb0490","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00262-022-03275-5","article-title":"TCR extracellular domain genetically linked to CD28, 2B4\/41BB and DAP10\/CD3 \u03b6-engineered NK cells mediates antitumor effects","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.humimm.2024.111207_bb0495","series-title":"Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma","first-page":"106656","volume":"188","author":"Peng","year":"2023"},{"issue":"2","key":"10.1016\/j.humimm.2024.111207_bb0500","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"10.1016\/j.humimm.2024.111207_bb0505","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.humimm.2024.111207_bb0510","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.humimm.2024.111207_bb0515","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.2147\/CMAR.S253565","article-title":"DNAM1 and 2B4 costimulatory domains enhance the cytotoxicity of anti-GPC3 chimeric antigen receptor-modified natural killer cells against hepatocellular Cancer cells in vitro","volume":"12","author":"Huang","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.humimm.2024.111207_bb0520","series-title":"CD137 (4-1BB) signalosome: complexity is a matter of TRAFs","first-page":"2618","volume":"9","author":"Zapata","year":"2018"},{"issue":"6","key":"10.1016\/j.humimm.2024.111207_bb0525","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2004-03-0798","article-title":"Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells","volume":"105","author":"De Palma","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.humimm.2024.111207_bb0530","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nbt1216","article-title":"Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration","volume":"24","author":"Montini","year":"2006","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.humimm.2024.111207_bb0535","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/10408363.2019.1633512","article-title":"Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects","volume":"56","author":"Poorebrahim","year":"2019","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"9","key":"10.1016\/j.humimm.2024.111207_bb0540","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.humimm.2024.111207_bb0545","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3109\/10428194.2011.634048","article-title":"Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens","volume":"53","author":"Boissel","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.humimm.2024.111207_bb0550","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3109\/14653249.2012.700767","article-title":"Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications","volume":"14","author":"Lapteva","year":"2012","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1016\/j.humimm.2024.111207_bb0555","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J. Immunother Cancer"},{"issue":"7","key":"10.1016\/j.humimm.2024.111207_bb0560","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2014-02-556837","article-title":"Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15","volume":"124","author":"Imamura","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.humimm.2024.111207_bb0565","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.humimm.2024.111207_bb0570","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1158\/2326-6066.CIR-23-0151","article-title":"Sequential exposure to IL21 and IL15 during human natural killer cell expansion optimizes yield and function","volume":"11","author":"Zhang","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.humimm.2024.111207_bb0575","series-title":"Influence of irradiated peripheral blood mononuclear cells on both ex vivo proliferation of human natural killer cells and change in cellular property","first-page":"854","volume":"8","author":"Delso-Vallejo","year":"2017"},{"key":"10.1016\/j.humimm.2024.111207_bb0580","series-title":"Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer","first-page":"1","volume":"13","author":"Sakamoto","year":"2015"},{"key":"10.1016\/j.humimm.2024.111207_bb0585","series-title":"Optimization of large-scale expansion and cryopreservation of human natural killer cells for anti-tumor therapy","first-page":"4","volume":"18","author":"Min","year":"2018"},{"issue":"11","key":"10.1016\/j.humimm.2024.111207_bb0590","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jcyt.2016.06.013","article-title":"Expanded and armed natural killer cells for cancer treatment","volume":"18","author":"Shimasaki","year":"2016","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0595","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered, and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.humimm.2024.111207_bb0600","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14653240310001523","article-title":"Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy","volume":"5","author":"Tam","year":"2003","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.humimm.2024.111207_bb0605","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.4049\/jimmunol.174.7.3992","article-title":"IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors","volume":"174","author":"Marcenaro","year":"2005","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2024.111207_bb0610","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1084\/jem.20092029","article-title":"IL-7 and IL-15 independently program the differentiation of intestinal CD3\u2212 NKp46+ cell subsets from Id2-dependent precursors","volume":"207","author":"Satoh-Takayama","year":"2010","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.humimm.2024.111207_bb0615","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.4049\/jimmunol.174.3.1213","article-title":"Roles for common cytokine receptor \u03b3-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo","volume":"174","author":"Vosshenrich","year":"2005","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0620","doi-asserted-by":"crossref","first-page":"107","DOI":"10.21873\/anticanres.13085","article-title":"Culturing the human natural killer cell line NK-92 in Interleukin-2 and Interleukin-15 - implications for clinical trials","volume":"39","author":"T\u00f6rnroos","year":"2019","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.humimm.2024.111207_bb0625","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.exphem.2010.02.006","article-title":"Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression","volume":"38","author":"Decot","year":"2010","journal-title":"Exp. Hematol."},{"issue":"8","key":"10.1016\/j.humimm.2024.111207_bb0630","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1089\/10430349950018030","article-title":"Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy","volume":"10","author":"Tam","year":"1999","journal-title":"Hum. Gene Ther."},{"issue":"26","key":"10.1016\/j.humimm.2024.111207_bb0635","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.humimm.2024.111207_bb0640","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10254","key":"10.1016\/j.humimm.2024.111207_bb0645","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.humimm.2024.111207_bb0650","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.humimm.2024.111207_bb0655","first-page":"694","article-title":"STATs in NK-cells: the good, the bad, and the ugly","volume":"7","author":"Gotthardt","year":"2016","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.humimm.2024.111207_bb0660","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1073\/pnas.141224998","article-title":"Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway","volume":"98","author":"Baldassarre","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0665","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and Cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.humimm.2024.111207_bb0670","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071915","article-title":"Humanized mice are precious tools for preclinical evaluation of CAR T and CAR NK cell therapies","volume":"12","author":"Mhaidly","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0675","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0022-1759(93)90102-D","article-title":"Human natural killer cells: a convenient purification procedure and the influence of cryopreservation on cytotoxic activity","volume":"165","author":"Voshol","year":"1993","journal-title":"J. Immunol. Methods"},{"issue":"9","key":"10.1016\/j.humimm.2024.111207_bb0680","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/bloodadvances.2020001510","article-title":"Inducible MyD88\/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells","volume":"4","author":"Wang","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.humimm.2024.111207_bb0685","first-page":"678","article-title":"Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines","volume":"17","author":"Halama","year":"2011","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.humimm.2024.111207_bb0690","first-page":"80","article-title":"shp-2 gene knockout upregulates CAR-driven cytotoxicity of YT NK cells","volume":"24","author":"Subrakova","year":"2020","journal-title":"Vavilovskii Zhurnal Genet Selektsii"},{"issue":"5","key":"10.1016\/j.humimm.2024.111207_bb0695","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924004701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924004701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T21:12:11Z","timestamp":1740085931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885924004701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":139,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0198885924004701"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2024.111207","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor natural killer cell therapy: A systematic review of preclinical studies for hematologic and solid malignancies","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2024.111207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111207"}}